Evidence map›Paper›PMID 31346052›Full record

ArticleScience (New York, N.Y.)2019

Lowering ceramides to overcome diabetes.

Christine M Kusminski, Philipp E Scherer

Abstract readComment
PubMed Publisher
In one paragraph

Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Christine M KusminskiTouchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Philipp E SchererTouchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA. philipp.scherer@utsouthwestern.edu.

Funding

The role of AgRP/Auga-ALK pathway in FGF21's brain action on agingP01AG051459 · NIA · YALE UNIVERSITY · PI VISHWA DEEP DIXIT · 2016 to 2026
$25.7M
Novel Mechanisms Regulating the Adipocyte-Brain-Hepatocyte AxisP01DK088761 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI SCHERER, PHILIPP E · 2010 to 2019
$17.4M
Adiponectin, A Protein Secreted From Adipose TissueR01DK055758 · NIDDK · YESHIVA UNIVERSITY · PI SCHERER, PHILIPP E · 2000 to 2024
$10.9M
White Adipose Tissue Physiology, Mitochondrial Function and AdiponectinR01DK099110 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PHILIPP E SCHERER · 2013 to 2026
$6.7M
NIA NIH HHS P01 AG051459NIDDK NIH HHS P01 DK088761NIDDK NIH HHS R01 DK055758NIDDK NIH HHS R01 DK099110
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes MellitusFatty LiverInsulin ResistanceCeramidesHumansCeramides

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.